Laboratorio Reig Jofre (RJF) Stock Overview
A pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
RJF Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.73 |
| 52 Week High | €3.40 |
| 52 Week Low | €2.32 |
| Beta | 0.95 |
| 1 Month Change | 1.11% |
| 3 Month Change | 5.00% |
| 1 Year Change | -13.33% |
| 3 Year Change | 8.76% |
| 5 Year Change | -50.90% |
| Change since IPO | -28.53% |
Recent News & Updates
Recent updates
Reig Jofre Will Emerge Stronger Despite Temporary Setbacks
After reviewing Reig Jofre’s latest annual report and the Q1 2026 results, we are updating our 3-year fair value estimate to €3.29 per share , down from our previous €3.59 target published six months ago. The revision does not reflect a deterioration of the long-term business case, but rather a more realistic assessment of the pace of execution and margin recovery.Calculating The Fair Value Of Laboratorio Reig Jofre, S.A. (BME:RJF)
Key Insights Laboratorio Reig Jofre's estimated fair value is €3.07 based on 2 Stage Free Cash Flow to Equity With...These 4 Measures Indicate That Laboratorio Reig Jofre (BME:RJF) Is Using Debt Extensively
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...This Analyst Just Downgraded Their Laboratorio Reig Jofre, S.A. (BME:RJF) EPS Forecasts
The analyst covering Laboratorio Reig Jofre, S.A. ( BME:RJF ) delivered a dose of negativity to shareholders today, by...We Think Laboratorio Reig Jofre (BME:RJF) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Laboratorio Reig Jofre (BME:RJF) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...The Laboratorio Reig Jofre (BME:RJF) Share Price Has Gained 146%, So Why Not Pay It Some Attention?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...Is Laboratorio Reig Jofre (BME:RJF) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Laboratorio Reig Jofre (BME:RJF) Shareholders Booked A 47% Gain In The Last Year
It might be of some concern to shareholders to see the Laboratorio Reig Jofre, S.A. ( BME:RJF ) share price down 15% in...Shareholder Returns
| RJF | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 0.7% | 1.2% | 1.9% |
| 1Y | -13.3% | 10.7% | 24.0% |
Return vs Industry: RJF underperformed the Spanish Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: RJF underperformed the Spanish Market which returned 22.7% over the past year.
Price Volatility
| RJF volatility | |
|---|---|
| RJF Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in ES Market | 6.7% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: RJF has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: RJF's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,400 | Ignasi Reig | reigjofre.com/en |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| RJF fundamental statistics | |
|---|---|
| Market cap | €222.25m |
| Earnings (TTM) | €4.42m |
| Revenue (TTM) | €335.01m |
Is RJF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RJF income statement (TTM) | |
|---|---|
| Revenue | €335.01m |
| Cost of Revenue | €138.03m |
| Gross Profit | €196.98m |
| Other Expenses | €192.56m |
| Earnings | €4.42m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 31, 2026
| Earnings per share (EPS) | 0.054 |
| Gross Margin | 58.80% |
| Net Profit Margin | 1.32% |
| Debt/Equity Ratio | 36.7% |
How did RJF perform over the long term?
See historical performance and comparisonDividends
Does RJF pay a reliable dividends?
See RJF dividend history and benchmarks| Laboratorio Reig Jofre dividend dates | |
|---|---|
| Ex Dividend Date | May 21 2026 |
| Dividend Pay Date | Jun 02 2026 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 9 days |
Does RJF pay a reliable dividends?
See RJF dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 21:57 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laboratorio Reig Jofre, S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francisco Ruiz | BNP Paribas |
| Alfredo Echevarria Otegui | Lighthouse-IEAF Servicios de Analisis |
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |